Human medicines: highlights of 2019

Human_medicines_highlights_2019-EMA-paper-image

  
The European Medicine Agency (EMA) has published an overview of its key recommendations in 2019 on the authorisation and safety monitoring of medicines for human use. 

Once a medicine is authorised by the European Commission and prescribed to patients, EMA and the EU Member States continuously monitor its quality and benefit-risk balance and take regulatory action when needed. Measures can include a change to the product information, the suspension or withdrawal of a medicine, or a recall of a limited number of batches.

In 2019, EMA recommended 66 medicines for marketing authorisation. Of these, 30 had a new active substance which had never been authorised in the EU before. The infographic includes a selection of medicines that represent significant progress in their therapeutic areas. 
An overview of some of the most notable recommendations is also provided.

Access EMA publication here

 

This website is developed with the financial support of an operating grant of the Rights, Equality and Citizenship Programme of the European Commission. The contents of the articles are the sole responsibility of AGE Platform Europe and can in no way be taken to reflect the views of the European Commission.